- Capital Cube•2 months ago
Click here to see latest analysisProtalix Biotherapeutics, Inc. reports financial results for the quarter ended March 31, 2016.HighlightsSummary numbers: Revenues of USD 0.68 million, Net Earnings of USD -8.53 million.Gross margins widened from -13.95% to 22.97% compared to the same period last year, operating (EBITDA) margins now -1,274.96% from -601.45%.Change in operating cash flow of […] (Read more...) The post Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 19, 2016 appeared first on CapitalCube.
- Associated Press•3 months ago
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 9 cents. The drug developer posted revenue of $679,000 in the period. The company's shares closed at 80 cents. A year ago, ...
|Bid||0.64 x 6200|
|Ask||0.65 x 2400|
|52wk Range||0.61 - 1.75|
|Day's Range||0.64 - 0.65|
|Avg Vol (3m)||76,407|
As of 4:00 PM EDT. Market closed.